TV-1106 + somatropin

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 24/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Growth Hormone-Deficiency

Conditions

Growth Hormone-Deficiency

Trial Timeline

Apr 30, 2014 → Aug 31, 2016

NCT ID

NCT02092077

About TV-1106 + somatropin

TV-1106 + somatropin is a phase 2 stage product being developed by Teva Pharmaceutical Industries for Growth Hormone-Deficiency. The current trial status is terminated. This product is registered under clinical trial identifier NCT02092077. Target conditions include Growth Hormone-Deficiency.

What happened to similar drugs?

11 of 20 similar drugs in Growth Hormone-Deficiency were approved

Approved (11) Terminated (1) Active (9)

✅PEG-somatropinSun PharmaceuticalApproved

✅PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved

✅Saizen® solution for injection (referred as Saizen®)MerckApproved

✅Saizen + SaizenMerckApproved

✅EverolimusNovartisApproved

✅somatropin + somatropin + somatropinNovo NordiskApproved

✅somatropin + placeboNovo NordiskApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02092077	Phase 2	Terminated	Apr 30, 2014	Aug 31, 2016	Growth Hormone-Deficiency

Competing Products

20 competing products in Growth Hormone-Deficiency

See all competitors

Product	Company	Stage	Hype Score
Somatropin	Eli Lilly	Phase 3	40
Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)	Eli Lilly	Pre-clinical	26
HER3-DXd	Daiichi Sankyo	Pre-clinical	26
Erlotinib	Astellas Pharma	Phase 2	27
radio-labeled naquotinib + naquotinib	Astellas Pharma	Phase 1	21
pegylated Somatropin + pegylated Somatropin + Jintropin AQ	Sun Pharmaceutical	Phase 2	35
PEG-somatropin	Sun Pharmaceutical	Approved	39
PEG-somatropin + PEG-somatropin	Sun Pharmaceutical	Approved	39
PEG-somatropin	Sun Pharmaceutical	Phase 3	40
Somatropin + Somatropin	Eli Lilly	Phase 3	40
Somatropin + Somatropin	Eli Lilly	Phase 3	40
somatropin, rDNA origin, for injection	Eli Lilly	Phase 3	40
Sterile becaplermin gel vs. sterile placebo gel treatment 1	Johnson & Johnson	Pre-clinical	26
ABT-414	AbbVie	Pre-clinical	26
Saizen® A + Saizen® B	Merck	Phase 3	40
Saizen® solution for injection (referred as Saizen®)	Merck	Approved	43
Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)	Merck	Phase 3	40
Saizen + Saizen	Merck	Approved	43
Miransertib	Merck	Phase 2	39
Miransertib	Merck	Phase 1/2	24